CLYM (Climb Bio) ROC (Joel Greenblatt) %: -7,995.27% (As of Mar. 2026)


CLYM Climb Bio Inc CLYM
22 GF Score
Price $13.22
! 3 Warning Signs
View Full Analysis

What is Climb Bio ROC (Joel Greenblatt) %?

Climb Bio CLYM -2.51% 22 ROC (Joel Greenblatt) % is -7,995.27% as of Mar. 2026. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,319 Biotechnology companies, Climb Bio ranks worse than 88.78% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Climb Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -7,995.27%.

The historical rank and industry rank for Climb Bio's ROC (Joel Greenblatt) % or its related term are showing as below:

CLYM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12022.39   Med: -9371.9   Max: -6838.06
Current: -7936.06

During the past 7 years, Climb Bio's highest ROC (Joel Greenblatt) % was -6838.06%. The lowest was -12022.39%. And the median was -9371.90%.

CLYM's ROC (Joel Greenblatt) % is ranked worse than
88.78% of 1319 companies
in the Biotechnology industry
Industry Median: -291.86 vs CLYM: -7936.06

Climb Bio's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Climb Bio  (NAS:CLYM) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Climb Bio ROC (Joel Greenblatt) % Related Terms


Climb Bio ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Climb Bio's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Climb Bio ROC (Joel Greenblatt) % Chart

Climb Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial 0.00 -9,582.80 -12,022.39 -6,838.06 -9,161.00

Climb Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16,152.98 -6,176.14 -6,574.83 -9,227.02 -7,995.27

CLYM vs XOMA, CTMX, ALLO: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Climb Bio's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Climb Bio ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Climb Bio's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Climb Bio's ROC (Joel Greenblatt) % falls into.


CLYM
22GF Score
Climb Bio Inc CLYM
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Climb Bio ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.769) - (6.669 + 0 + 0.059)
=-1.959

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.84) - (3.695 + 0 + 0.113)
=0.032000000000004

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Climb Bio for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-60.844/( ( (0.793 + max(-1.959, 0)) + (0.697 + max(0.032000000000004, 0)) )/ 2 )
=-60.844/( ( 0.793 + 0.729 )/ 2 )
=-60.844/0.761
=-7,995.27 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -7,995.27% mean?
Climb Bio (CLYM) has a ROC (Joel Greenblatt) % of -7,995.27% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Climb Bio and its competitors. According to the industry distribution chart, Climb Bio ranks #1171 out of 1319 companies in the Biotechnology industry, placing it in the top 88.8%.
Is Climb Bio's ROC (Joel Greenblatt) % too high?
Climb Bio's current ROC (Joel Greenblatt) % is -7,995.27%. Based on the distribution chart, Climb Bio ranks #1171 out of 1319 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's ROC (Joel Greenblatt) % compare to XOMA and CTMX?
According to the Biotechnology industry distribution chart, Climb Bio ranks #1171 out of 1319 companies for ROC (Joel Greenblatt) %. This places Climb Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Climb Bio and its competitors. Climb Bio's current ROC (Joel Greenblatt) % is -7,995.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current ROC (Joel Greenblatt) % of -7,995.27%. The current ROC (Joel Greenblatt) % is -7,995.27%. Climb Bio's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Climb Bio (CLYM), the current ROC (Joel Greenblatt) % is -7,995.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Climb Bio Business Description

Address 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score

Get the complete analysis for CLYM

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.22
Price